Key result
Sacubitril/valsartan lacks strong evidence for reducing hyperkalemia and worsening renal function in HF with renal dysfunction.
Why the study?
Heart failure and renal dysfunction frequently coexist, but strong evidence supporting sacubitril/valsartan to reduce hyperkalemia and worsening renal function in these patients is lacking.
Does sacubitril/valsartan improve cardiac and renal outcomes in patients with heart failure and renal dysfunction compared to angiotensin-converting enzyme inhibitors?
Does sacubitril/valsartan improve cardiac and renal outcomes in patients with heart failure and renal dysfunction compared to angiotensin-converting enzyme inhibitors?
The administration of sacubitril/valsartan in heart failure patients with renal dysfunction requires a careful balance between benefits and risks due to a lack of strong evidence regarding hyperkalemia and worsening renal function.
No takes yet. Share an insight, caveat, or question.
Caution advised with sacubitril/valsartan in HF and renal dysfunction; leaves open renal outcome superiority versus ACEIs.
Zhu et al. (2024) conducted a review in Heart failure with renal dysfunction. Sacubitril/valsartan (ARNI) vs. Angiotensin-converting enzyme inhibitor was evaluated. Sacubitril/valsartan lacks strong evidence for reducing the absolute risk of hyperkalemia and worsening renal function in heart failure patients with renal dysfunction, requiring careful risk balance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: